Repositioning Candidate Details
| Candidate ID: | R1576 |
| Source ID: | DB15731 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells |
| Synonyms: | Allogeneic donor CD362 enriched human umbilical cord-derived mesenchymal stromal cells; ORBCEL C™; Orbcel-C; REALIST ORBCEL-C |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | ORBCEL-C™ is the trade name of a product composed of highly purified stromal cells derived from the human umbilical cord. The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor’s cells can be given to other unrelated patients. These cells are CD362 enriched umbilical cord-derived mesenchymal stem cells (UC-MSCs); UC-MSCs share stemness markers with both embryonic stem cells (ESCs) and adult mesenchymal stem cells (MSCs); this feature allows them to be hypoimmunogenic and non-inducible for tumorigenesis. Regarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified on MSCs with enhanced clonogenicity and immunomodulatory properties. Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | The mesenchymal stem cells (MSCs) of ORBCEL-C™ act through release of factors which reduce inflammatory responses, promote blood vessel formation, and have the ability to demonstrate immunomodulatory effects. Allogeneic UC-MSCs are also being investigated in orthopedic applications for cartilage and bone regeneration; these UC-MSCs are a valuable allogeneic source of cells as these cells are from a discarded material with virtually unlimited availability. Specifically to orthopedics, UC-MSCs have potential for treatment of chondral and osteochondral lesions, and bone defects as a universal off-the-shelf product. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| S15 | Cell therapy | Mesenchymal stem cells; Stem cell therapy | -- | -- | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|